Summary
"Transcatheter Therapeutics (TCT) 2009: Conference Review and Analysis" report is an essentially source of information and analysis on the happenings in Transcatheter Therapeutics (TCT) 2009, scheduled to be held from September 21-25, 2009 in San Francisco, US. The report provides key data and information on the products showcased in the conference. The report also provides answers to questions like: what are the emerging trends in the cardiovascular devices market? Which are the upcoming technologies and companies? Which sectors are expected to grow and why? What products are in pipeline and how would they impact sector growth? This report also provides an insight into key studies and trials being held, with up-to date results and analysis.
Scope
-The report covers information and analysis on product and technology launched at the conference.
-The report provides market size data and information on the cardiovascular devices market with information for seven categories-Cardiac Rhythm Management (CRM), cardiovascular monitoring and diagnostic devices, cardiovascular prosthetic devices, cardiovascular surgery, interventional cardiology, peripheral vascular devices and electrophysiology.
-Analysis and review of the key products and technologies within each segment and sub-segments that will impact the future of cardiovascular devices.
-Review of key industry trends and events which are likely to impact and change the dynamics of the global cardiovascular devices markets in the long run.
-In-depth analysis of the studies and clinical trials presented at the conference.
-List of key companies presenting at the conference with company and product profiles.
-The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by 's team of industry experts.
Reasons to buy
-Develop business strategies by understanding the trends shaping and driving the global cardiovascular devices market.
-Organize your sales and marketing efforts by identifying the prevalent and expected competitive landscape in different cardiovascular devices markets.
-Design and develop your product development, marketing and sales strategies by identifying the market segments poised for a strong growth.
-Identify key players who are best positioned to take advantage of the emerging market opportunities.
-Exploit in-licensing and out-licensing opportunities by identifying products that are most likely to ensure a robust return.
-What's the next being thing in the cardiovascular devices market landscape?-Identify, understand and capitalize.
Table of Contents
1.1 List of Tables 5
1.2 List of Figures 5
2 Transcatheter Cardiovascular Therapeutics (TCT) 2009-Conference Review and Analysis 6
2.1 Summary 6
2.2 Key Takeaways of TCT 2009 7
2.2.1 Drug Eluting Stents (DES) Pipeline 7
2.2.2 The Hybrid Cath Lab Operating Rooms (ORs) 7
2.2.3 Emerging Role of Genetics in Predicting Risk of Disease 7
3 TCT 2009-Interventional Cardiology Outlook 8
3.1 Market Profile 8
3.2 Competitive Landscape 9
3.3 Key Companies at TCT 2009 10
3.3.1 Boston Scientific Corporation 10
3.3.2 Abbott Vascular 11
3.3.3 Medtronic Inc 14
3.3.4 Cordis Corp. 15
3.3.5 Spectranetics 15
3.3.6 Cardiva Medical Inc 16
4 TCT 2009-Peripheral Vascular Devices Outlook 17
4.1 Market Overview 17
4.2 Competitive Landscape 18
4.3 Key Companies at TCT 2009 19
4.3.1 Pathway Medical Technologies 19
4.3.2 Cook Medical Incorporated 19
4.3.3 Minnow Medical, Inc 20
4.3.4 Abbott Vascular 21
4.3.5 Terumo Corporation 21
4.3.6 Vascular Solutions Inc 22
5 TCT 2009-Prosthetic Heart Valves Outlook 23
5.1 Market Overview 23
5.2 Key Companies at TCT 2009 24
5.2.1 Coherex Medical Inc 24
5.2.2 Evalve Inc 25
5.2.3 Mardil Inc 26
6 TCT 2009-Ventricular Assist Devices Outlook 27
6.1 Market Overview 27
6.2 Key Companies at TCT 2009 28
6.2.1 BIOMED Inc. 28
6.2.2 CardiacAssist Inc. 29
7 Other Companies at TCT 2009 30
7.1 Morris Innovative 30
7.1.1 Company Profile 30
7.1.2 Product Profile 30
7.1.3 Clinical Trial 30
7.2 ProSolv CardioVascular 31
7.2.1 Company Profile 31
7.2.2 Product Presented at TCT 2009 31
7.3 TeraRecon, Inc. 32
7.3.1 Company Profile 32
7.3.2 Product Presented at TCT 2009 32
7.4 Ardian Inc. 33
7.4.1 Company Profile 33
7.4.2 Product Presented at TCT 2009 33
7.4.3 Clinical Trial 33
7.5 PLC Systems Inc. 34
7.5.1 Company Profile 34
7.5.2 Product Presented at TCT 2009 34
7.5.3 Clinical Trial 34
7.6 Vascular Solutions 34
7.6.1 Company Profile 34
7.6.2 Product Presented at TCT 2009 34
8 Appendix 35
8.1 Research Methodology 35
8.2 Secondary Research 36
8.3 Primary Research 37
8.4 Models 37
8.5 Forecasts 38
8.6 Expert Panel Validation 38
8.7 Currency Conversion 39
8.8 Contact Us 40
8.9 Disclaimer 40
1.1 List of Tables
Table 1: Interventional Cardiology, Global, Revenue ($m), 2000-2015 9
Table 2: TAXUS Express Horizon's AMI Trial, Two Year Follow up Results 10
Table 3: XIENCE V (PROMUS) Spirit III Trial, Three Year Results 12
Table 4: XIENCE V (PROMUS) Spirit III Trial, in Diabetic Patients 12
Table 5: Peripheral Vascular Devices, Global, Revenue ($m), 2000-2015 18
Table 6: Prosthetic Heart Valve, Global, Revenue ($m), 2000-2015 24
Table 7: Ventricular Assist Devices, Global, Revenue ($m), 2000-2015 28
Table 8: FISH closure device Clinical Trial Details 31
Table 9: USD to Local Currency, Average Exchange Rate 2008 39
1.2 List of Figures
Figure 1: Interventional Cardiology, Global, Revenue ($m), 2000-2015 8
Figure 2: Interventional Cardiology, Company Shares, 2009 9
Figure 3: Peripheral Vascular Devices, Global, Revenue ($m), 2000-2015 17
Figure 4: Peripheral Vascular Device, Company Shares, 2009 18
Figure 5: Prosthetic Heart Valve, Global, Revenue ($m), 2000-2015 23
Figure 6: Ventricular Assist Devices, Global, Revenue ($m), 2000-2015 27
Figure 7: Methodology 36
